Top Story

Atherosclerosis risk increased among men with diabetes, low testosterone

October 17, 2014

A greater risk for developing atherosclerosis is found among middle-aged men with low testosterone and type 2 diabetes, according to recent study findings published in The Journal of Clinical Endocrinology & Metabolism.

“Our study indicates a strong association between low testosterone concentration and the severity of atherosclerotic plaques as well as other key atherosclerotic markers in middle-aged men with type 2 diabetes,” Javier Mauricio Farias, MD, of the Hospital Universitario Sanatorio Guemes in Buenos Aires, said in a press release. “The results of our study advance our understanding of the interplay between low testosterone and cardiovascular disease in patients with diabetes.”

Meeting News Coverage

Biguanides, liraglutide reduced CVD risk in type 2 diabetes

September 24, 2014
Patients with type 2 diabetes treated with biguanides and liraglutide have a reduced risk for ischemic heart disease, heart failure and stroke, according to research…
figure Meeting News Coverage

Higher plasma levels linked to CV complications in type 1 diabetes

September 18, 2014
Cardiovascular complications are associated with higher plasma levels in patients with type 1 diabetes, according to a presenter at the 50th European Association for the…
In the Journals

Age, diabetes duration increases risk for macrovascular complications

September 12, 2014
For patients with type 2 diabetes, macrovascular events and death are associated with age or age at diagnosis and diabetes duration, according to research published in…
CME
figure

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

This activity is supported by an educational grant from Genentech.

Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM)…
More »
CME
figure

Lipid Forum II Highlights

This activity is supported by an educational grant from Genentech.

Risk stratification and appropriate therapies for various dyslipidemias remain difficult concepts for practitioners…
More »

Filter By:

In the Journals

Knowing modifiable risk factors may reduce CV death in type 2 diabetes

July 9, 2014
Determining vascular calcification and modifiable risk factors for heart disease could provide patients with type 2 diabetes the insight needed to…
Meeting News Coverage

Higher obesity increases odds for cardiovascular, cancer, diabetes deaths

July 8, 2014
Adults with class III obesity are more likely to die from all causes than those within normal weight range, but particularly from heart disease…
In the Journals Perspective

'Bundled' management reduced diabetes-related vascular complications

July 3, 2014
A team-based model with an all-or-none or “bundled” approach to primary care reduced the risk for myocardial infarction, stroke and…
In the Journals

Sitagliptin may increase hospitalizations in patients with diabetes, HF

July 2, 2014
Recent study results found that sitagliptin use by patients with type 2 diabetes and HF may increase the risk for HF-related…
In the Journals

CV risk control differs by sex for patients with type 2 diabetes

July 2, 2014
Composite control of cardiovascular risk factors varies by sex for patients with type 2 diabetes, with women’s significantly lower than…
Meeting News Coverage

RYGB adds CV, quality-of-life benefits for obesity, type 2 diabetes

July 1, 2014
CHICAGO — Roux-en-Y gastric bypass surgery could bring additional benefits for some patients with obesity and type 2 diabetes, according to…
In the Journals

Homeless men boosted health playing pick-up soccer

June 29, 2014
As World Cup competition continues, a timely study published in the Scandinavian Journal of Medicine & Science in Sports showed that playing…
In the Journals

CABG, newer-generation DES yielded similar mortality rates in patients with diabetes

June 26, 2014
Comparable mortality rates were reported for patients with diabetes treated with CABG or PCI using a cobalt-chromium everolimus-eluting…
FDA News

FDA: No clear link between olmesartan, CV risk among patients with diabetes

June 24, 2014
The FDA today announced that a safety review of olmesartan indicates no increased risk for CV events among patients with diabetes.According to a…
Meeting News Coverage Perspective

Empagliflozin reduced BP for patients with type 2 diabetes, hypertension

June 23, 2014
CHICAGO — In patients with type 2 diabetes and hypertension, empagliflozin significantly reduced BP in addition to improving blood glucose…
More Headlines »